Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PHGDH | O43175 | 1/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543569 | 0.90 | FAAH (0.66) | ALDH1A1LMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL10825084 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL27791391 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL2850013 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL611401 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL5537445 | 0.83 | ATM (0.64) | ALDH1A1LMNASMN1; SMN2KMT2AKDM4E | |
| SCHEMBL9510221 | 0.83 | ALDH1A1 (0.62) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL1943497 | 0.82 | HRH3 (0.75) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL16357989 | 0.82 | ALDH1A1 (0.66) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 | |
| SCHEMBL7973808 | 0.82 | LMNA (0.67) | ALDH1A1LMNASMN1; SMN2KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552914-B1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-11-11 | — | — | EP | claimed |
| US-9029387-B2 | Benzonaphthyridinamines as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2015-05-12 | — | — | US | claimed |
| EP-2552914-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2013-02-06 | — | — | EP | claimed |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-10 | — | — | US | claimed |
| WO-2011116867-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2011-09-29 | — | — | WO | claimed |
| CN-114146080-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114146081-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114146079-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-113244185-A | Pharmaceutical composition containing dimethyl fumarate | 比奥根玛公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-2552914-B1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9029387-B2 | Benzonaphthyridinamines as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885LMNA 4323/4885SMN1; SMN2 4306/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885LMNA 4152/4885SMN1; SMN2 3985/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ALDH1A1 351/4885LMNA 4828/4885SMN1; SMN2 4399/4885 |
| US-20130012505-A1 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | ENPP2, LYPLAL1, LYPLA1 | ALDH1A1 3057/4885LMNA 990/4885SMN1; SMN2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.